Analysed Royalty Pharma plc (RPRX:NASDAQ) News Sources
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
TMCnet
Chancery Royalty Ltd: Chancery Royalty Secures US$20 Million Royalty with KEFI Gold & Copper Plc for Tulu Kapi Gold Project
FinanzNachrichten.de
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Markets Insider
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Markets Insider
Around £22 now, GSK’s share price looks 50% undervalued to me after strong 2025 results
Yahoo Finance UK
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
PR Newswire UK
What is the current price of Royalty Pharma plc (RPRX:NASDAQ)?
The current price of Royalty Pharma plc (RPRX:NASDAQ) is $45.36.
Royalty Pharma plc (RPRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of Royalty Pharma plc (RPRX:NASDAQ) since the previous trading day is $0.21.
Royalty Pharma plc (RPRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of Royalty Pharma plc (RPRX:NASDAQ) since the previous trading day is 0.47%.
What is This Week's average sentiment score for Royalty Pharma plc (RPRX:NASDAQ)?
This Week's average sentiment score for Royalty Pharma plc (RPRX:NASDAQ) is 73 out of 100.
What is This Week's average sentiment for Royalty Pharma plc (RPRX:NASDAQ)?
This Week's sentiment for Royalty Pharma plc (RPRX:NASDAQ) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.